SCHEMBL838368

SCHEMBL838368

CNC(=O)c1cccc(-c2cnn3c(Br)c(NC(=O)OC)nc3c2)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 6/20 0.49
FGFR3 P22607 6/20 0.49
CDK8 P49336 1/20 0.44
NTRK1 P04629 1/20 0.42
PDGFRB P09619 1/20 0.42
KIT P10721 1/20 0.42
FLT3 P36888 1/20 0.42
PIK3CG P48736 1/20 0.42
FYN P06241 4/20 0.41
PIK3CA P42336 1/20 0.40
NR4A2 P43354 1/20 0.40
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
LRRK2 Q5S007 1/20 0.37
PLAU P00749 1/20 0.36
SYK P43405 1/20 0.36
JAK2 O60674 1/20 0.35
JAK3 P52333 1/20 0.35
POLQ O75417 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL835392 0.78 FGFR1 (0.48) FGFR1FGFR3CDK8NTRK1PDGFRB
SCHEMBL837839 0.76 FGFR1 (0.65) FGFR1FGFR3CDK8NTRK1PDGFRB
SCHEMBL12448288 0.73 FGFR1 (0.66) FGFR1FGFR3CDK8NTRK1PDGFRB
SCHEMBL3757138 0.71 FGFR1 (0.50) FGFR1FGFR3CDK8NTRK1PDGFRB
SCHEMBL835076 0.69 FGFR1 (0.48) FGFR1FGFR3CDK8NTRK1PDGFRB
SCHEMBL837898 0.69 CDK8 (0.55) FGFR1FGFR3CDK8NTRK1PDGFRB
SCHEMBL837206 0.68 FGFR3 (0.70) FGFR1FGFR3CDK8NTRK1PDGFRB
SCHEMBL13702375 0.68 HDAC8 (0.68) CDK8PIK3CGFYNPIK3CANR4A2
SCHEMBL835840 0.67 FGFR3 (0.73) FGFR1FGFR3CDK8NTRK1PDGFRB
SCHEMBL2340954 0.67 FGFR3 (0.66) FGFR1FGFR3CDK8NTRK1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143253-B2 Organic compounds NOVARTIS AG (CH) 2012-03-27 US disclosed
US-8143253-B2 Organic compounds NOVARTIS AG (CH) 2012-03-27 US disclosed
US-8143253-B2 Organic compounds NOVARTIS AG (CH) 2012-03-27 US disclosed
EP-2183027-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-08-31 EP disclosed
US-20100204235-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-08-12 US disclosed
US-20100204235-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-08-12 US disclosed
US-20100204235-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-08-12 US disclosed
EP-2183027-A1 ORGANIC COMPOUNDS Novartis Ag (CH) 2010-05-12 EP disclosed
WO-2009013335-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-01-29 WO disclosed
WO-2009013335-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204235-A1 ORGANIC COMPOUNDS ALK, OR10J3, FFAR4 FGFR1 20/4885FGFR3 81/4885CDK8 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.